Research Use Only. This page compares research identities, molecular architecture, receptor-family context and evidence limitations. It does not provide selection advice for pigmentation, appetite, sexual function, administration, dosing or any human outcome.
MT-I, MT-II and PT-141 are related to melanocortin research but are not interchangeable labels. The useful comparison starts with the named molecular entity, then asks which receptor-family question is being studied, what exact product form is documented, and which evidence layer actually supports the claim.
Comparison matrix
| Comparison field | Melanotan I / MT-I | Melanotan II / MT-II | PT-141 / bremelanotide |
|---|---|---|---|
| Commercial owner | Melanotan I (MT1) 10mg | Melanotan II (MT2) 10mg | PT-141 (Bremelanotide) 10mg |
| Structural architecture | Literature treats MT-I/afamelanotide as a linear melanocortin analogue. Product-specific form and salt remain documentation questions. | Literature treats MT-II as a cyclic melanocortin analogue. Do not infer the exact supplied form from that broad identity. | PT-141/bremelanotide is a distinct melanocortin analogue. The exact product form must be documented independently. |
| Receptor-family context | Melanocortin receptor-family research, including MC1R-related pharmacology, is relevant at the literature level. | Melanocortin receptor-family profile should be read from current primary assay literature rather than fixed, unsourced potency tables. | Melanocortin receptor-family research context; do not describe it as perfectly selective or claim complete absence of other receptor activity without direct current assay evidence. |
| Identity / mass field | Verify sequence, counter-ion and mass against the specific material. MT-I shares sequence-level overlap with afamelanotide but this does not prove medicinal-product equivalence. | Verify exact cyclic structure, form and mass from product documentation. | Verify exact active moiety and form; branded medicine information is not a substitute for an RUO product record. |
| Analytical verification | HPLC and MS can support identity/composition questions when interpreted against expected product form. | Use method-aware peptide identity and chromatographic documentation; no universal purity threshold is implied. | Use product-specific analytical documentation and do not infer pharmaceutical equivalence from the name. |
| Evidence layer | Biochemical, pharmacology, clinical and regulatory information should be kept distinct. | Biochemical and preclinical receptor research must not be converted into consumer selection claims. | Mechanistic, clinical and regulatory sources may exist for bremelanotide as a medicine, but they remain separate from the RUO listing. |
| Key limitation | Regulated afamelanotide/Scenesse information must not be transferred to a separate RUO material. | Do not use a category label to establish a predictable receptor or outcome profile. | Do not use branded-medicine information to establish the identity, suitability or use of the RUO product. |
Evidence context and regulatory separation
Primary and review literature describes melanocortin analogues by molecular architecture and receptor pharmacology.[1] The correct scientific comparison is therefore pathway-aware, not outcome-ranked. A receptor-family statement does not establish a consumer benefit, an administration route, a response profile or an appropriate human use.
MT-I has a sequence relationship to afamelanotide/Scenesse® that must be stated carefully: a sequence-level relationship does not confirm the same pharmaceutical presentation, approval status, formulation, quality system or use. Likewise, PT-141 and bremelanotide medicine references must stay separate from the Core Research RUO product. The Research Use Only compliance boundary explains that distinction.
For the detailed pairwise questions, use MT-II versus PT-141 receptor-binding context and MT-I versus MT-II structural comparison. Those pages own the narrower comparison intents; this page is the broad matrix.
How to choose the correct research material for an experimental design
Set the comparison criteria before selecting a product owner: first, name the intended literature entity; second, identify whether the experiment concerns architecture, receptor-family pharmacology or analytical identity; third, confirm the exact product form; and finally, separate biochemical and preclinical literature from human and regulatory sources. Use the Specialist Research Compounds Catalogue only to reach the exact commercial owner, not as evidence that the three materials are interchangeable.
For batch-level questions, consult the Certificate of Analysis portal. A matrix cannot demonstrate a batch’s form, mass, counter-ion, identity or chromatographic composition.
What this comparison does not establish
This matrix does not rank MT-I, MT-II or PT-141, does not provide guidance for tanning, pigmentation, appetite, sexual function or any human outcome, and does not provide a preparation or administration method. It does not claim that any generic research material is the same as a licensed medicine.
Related research resources
- Specialist Research Compounds Catalogue
- Melanotan I, Melanotan II and PT-141
- MT-I versus MT-II comparison
- MT-II versus PT-141 comparison
- Research Use Only compliance boundary
References
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialisation. Peptides. 2006. DOI. Used for identity and historical context only.
- Delhanty PJD, et al. Melanocortin 1 receptor: pharmacological and therapeutic aspects. International Journal of Molecular Sciences. 2023. DOI. Used for receptor-family context, not outcome selection.
- US Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. FDA label. Used only to distinguish a regulated medicine context from the RUO product.